



IN THE CLAIMS

1. (canceled)
2. (canceled)
3. (currently amended) A pharmaceutical composition for the treatment of inflammation according to claim 2 consisting essentially of the compound of formula (IA)



and meloxicam of formula



or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

4. (canceled)
5. (canceled)
6. (canceled)
7. (canceled)
8. (canceled)

9. (withdrawn – previously presented) A method for the prevention or treatment of a disease or disorder selected from the group consisting of arthritis, including rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus, and juvenile arthritis, asthma, hay fever, atopic dermatitis, rhinitis, bronchitis, COPD, cystic fibrosis, psoriasis, scleroderma, morbus bechterew, sarcoidosis, tumor metastasis, morbus crohn, colitis ulcerosa, IBD, multiple sclerosis, arteriosclerosis, arteritis, myocardial infarction, stroke, coronary heart disease which method comprises administration of effective amounts of a composition according to claim 2 to a patient in need thereof in a combined form, or separately or separately and sequentially.



10. (withdrawn – previously presented) A method according to claim 9 for the prevention or treatment of rheumatoid arthritis, atopic dermatitis and coronary heart disease.

11. (withdrawn – previously presented) A method for the manufacture of a medicament for the prevention or treatment of disease or disorder selected from the group consisting of arthritis, including rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis, asthma, bronchitis, COPD and cystic fibrosis comprising mixing a LTB₄ antagonist according to claim 2 and meloxicam in a combined form.

12. (withdrawn – previously presented) The method according to claim 11 wherein the medicament for the prevention or treatment of rheumatoid arthritis, atopic dermatitis and coronary heart disease.


13. (currently amended) A pharmaceutical kit ~~comprising at least for the treatment of inflammation consisting essentially of~~ two separate unit dosage forms (A) and (B):

(A) comprises a composition containing a LTB₄ antagonist, of formula (I) (IA)



wherein

R represents a hydrogen atom or a group of formula $-\text{CO}_2\text{R}'$, in which R' represents a C_{1-6} alkyl, an optionally substituted phenyl or an optionally substituted benzyl group, wherein the optional substituents are selected from halogen atoms, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, nitro, C_{1-6} haloalkyl and C_{1-6} haloalkoxy groups, and A is a group selected from the formula (A1):



or a tautomer, a pharmaceutically acceptable salt or solvate thereof and optionally a pharmaceutically acceptable carrier, and

(B) comprises meloxicam, and optionally a pharmaceutically acceptable carrier or excipient.

14. (previously presented) A pharmaceutical formulation according to claim 3 which is suitable for oral, intravascular, intraperitoneal, subcutaneous, intramuscular or topical administration.

15. (currently amended) A pharmaceutical formulation according to claim 3 wherein the weight ratio of LTB₄ antagonist to meloxicam ranges from 50:1 to 1:300 1:10 up to 1:30.

16. (currently amended) A pharmaceutical formulation according to claim 3 wherein a single application dose contains 1 to ~~10,000~~ 5,000 milligrams of the combined active ingredients.

17. (previously presented) A pharmaceutical formulation according to claim 3 wherein the pharmaceutically acceptable carrier or excipient is a carbohydrate.

18. (new) A pharmaceutical formulation according to claim 3 wherein a single application dose contains 2-16 mg/kg meloxicam and 0.1-0.8 mg/kg formula IA, wherein the weight ratio of formula IA to meloxicam is 1:20.